Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. - Wikidata - awgldk - TriplyDB

Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease.

Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease.

http://www.wikidata.org/entity/Q36063269

about

Neuroprotective Transcription Factors in Animal Models of Parkinson Disease Neuroprotective Effects Against POCD by Photobiomodulation: Evidence from Assembly/Disassembly of the Cytoskeleton Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders Axonal Transport and Neurodegeneration: How Marine Drugs Can Be Used for the Development of Therapeutics Energy failure: does it contribute to neurodegeneration?Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson's Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque Mitochondrial quality, dynamics and functional capacity in Parkinson's disease cybrid cell lines selected for Lewy body expression.α-Synuclein oligomers impair neuronal microtubule-kinesin interplay.Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations.Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease ALS-linked FUS exerts a gain of toxic function involving aberrant p38 MAPK activation.Single and binge methamphetamine administrations have different effects on the levels of dopamine D2 autoreceptor and dopamine transporter in rat striatum.The Parkinsonian mimetic, 6-OHDA, impairs axonal transport in dopaminergic axons.Cutaneous neuropathy in Parkinson's disease: a window into brain pathology.Synuclein impairs trafficking and signaling of BDNF in a mouse model of Parkinson's disease.Nigrostriatal dynein changes in A53T alpha-synuclein transgenic mice.Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates.Neuron-to-neuron α-synuclein propagation in vivo is independent of neuronal injury Aging, Alzheimer's, and APOE genotype influence the expression and neuronal distribution patterns of microtubule motor protein dynactin-P50 Evidence for Immune Response, Axonal Dysfunction and Reduced Endocytosis in the Substantia Nigra in Early Stage Parkinson's Disease.Reductions in kinesin expression are associated with nitric oxide-induced axonal damage Analysis of YFP(J16)-R6/2 reporter mice and postmortem brains reveals early pathology and increased vulnerability of callosal axons in Huntington's disease.Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.Identification of Multiple QTLs Linked to Neuropathology in the Engrailed-1 Heterozygous Mouse Model of Parkinson's Disease.Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons.Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease.Lmx1a and Lmx1b regulate mitochondrial functions and survival of adult midbrain dopaminergic neurons Alteration of dynein function affects α-synuclein degradation via the autophagosome-lysosome pathway.HIV Glycoprotein Gp120 Impairs Fast Axonal Transport by Activating Tak1 Signaling Pathways.Trophic factor gene therapy for Parkinson's disease.Nanoparticles in the brain: a potential therapeutic system targeted to an early defect observed in many neurodegenerative diseases.Animal models of Parkinson's disease: a gateway to therapeutics?The pathomechanisms underlying Parkinson's disease.Impaired intracellular trafficking defines early Parkinson's disease Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinson's Disease.The prion hypothesis of Parkinson's disease.Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies.Dissecting the role of Engrailed in adult dopaminergic neurons--Insights into Parkinson disease pathogenesis Neurotrophic factors in Alzheimer's and Parkinson's diseases: implications for pathogenesis and therapy.Synaptic failure and α-synuclein.

P2860

Q26765693-146E85F5-E6A2-4D7A-9D89-F3541B635AFB Q26768713-C925006B-BD99-482A-8074-08DFBF47F013 Q26826093-6CF8F5A8-372D-49BD-A921-3E4A6332821A Q28079729-B493B271-25CB-4629-859D-7BD131C364F6 Q28389950-218C613B-D2F5-4162-9568-EF0D760F133A Q28554611-13012369-E5BB-4627-A295-F8A0398970B2 Q30422362-4C43C17F-0473-47BC-969E-0A4166168A30 Q30541822-6197EA5F-C5CB-4DC2-B02A-D94936DA6EFA Q30596172-3C04EBD1-9E6C-4D57-86F9-236F2D7DF598 Q30833636-BFE0DE1C-3D29-4683-9BB5-440E3A6D7C08 Q30849444-8A5AD7D3-1D45-43C1-9660-F41D97A66649 Q33580523-0B106352-BA09-4051-BAFB-DAFBF2B583E3 Q33593180-C23B19E2-FF67-4B1E-A2A5-0DBBC985A1D0 Q33764504-A8807A61-B759-4FF4-9723-D724893B3193 Q33819127-BFA38B5A-2AE1-48E8-8112-B74DB9E287C1 Q34140861-4FEB5444-D213-413C-8A7B-5F29973EF1B8 Q34195302-24C199FE-47E5-4C10-8ADC-5C4543ACE6F3 Q35206648-2154D05C-3116-42EA-96D5-82E0D431A9E6 Q35216177-9B1C0BA5-C100-4A4C-8707-BB74C9F26C9F Q35667600-A75198C0-2DC8-4FE8-9411-B659C32E6462 Q35884682-EBE09E84-88FD-4BAA-9580-D8B3F4582E12 Q35999314-C64EEA26-9442-48AC-9C12-D69518FA896A Q36011221-61031453-1485-4434-8F09-96E23F3B39B1 Q36109874-9AE53E08-41C9-4C33-9D0F-8DD9377F721A Q36293826-8D61BF42-00EF-4114-ADF1-0B0E51FCDBF0 Q36372732-82658974-D620-457C-BB5A-D98738018AB4 Q37142863-1D6E7437-6502-4C51-A09B-936D172C865E Q37420985-FD95D2A0-61A6-4702-8B29-DDB59AF374E1 Q37429252-3B8E07BD-785B-479C-8375-5A73B170C7EE Q38079792-81A54613-40D8-49B7-85AA-F7772D0FE670 Q38102579-D75C4734-42FB-4EF4-A9E5-91A350089C2E Q38155480-5C5C5F98-5973-49DF-88D5-8ADC3C339F6D Q38182660-9AD11515-8908-48C7-A6EF-1B13C987268F Q38256380-CEC1A160-6D5C-4510-972F-427D377D718C Q38260925-563BA9D4-6809-45FA-84FE-D2D9BB318F96 Q38418624-F7339C66-DEBD-4EBD-B10A-C92789C884FA Q38550428-8ED401DB-D284-4469-B25E-EBA19ED39B11 Q38605280-998D1774-269D-4CEF-8F85-19543A86AAA9 Q38701964-A26AFF50-C2B9-476A-9266-2D3374E5551D Q38704236-24BAC50F-299E-46AA-B7D4-FD7ABEF04E92

P2860

Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease.

http://www.wikidata.org/entity/Q36063269

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Alterations in axonal transpor ...... erimental Parkinson's disease.

@ast

Alterations in axonal transpor ...... erimental Parkinson's disease.

@en

type

label

Alterations in axonal transpor ...... erimental Parkinson's disease.

@ast

Alterations in axonal transpor ...... erimental Parkinson's disease.

@en

prefLabel

Alterations in axonal transpor ...... erimental Parkinson's disease.

@ast

Alterations in axonal transpor ...... erimental Parkinson's disease.

@en

P1433

Q36063269-EA6ADD72-DA9B-40C8-8E50-1340B49D32D3

P1476

Q36063269-E196F772-8ADE-40BC-9760-F4A89343EBA1

P2093

Q36063269-325400EC-3C7A-4A6E-8FED-5C471475A02E

Q36063269-39C7473D-5ED8-429D-A04B-AD847CBAA445

Q36063269-42990F1D-4BBC-43EC-96DE-518E5BE4F46F

Q36063269-61FDC0C3-FE11-435B-892B-2F4D4E6D828D

Q36063269-6E852B8A-25D2-4734-9D96-36BF898681E4

P2860

Q36063269-07295469-BC99-4D68-A2E5-5FFF7AAA1227

Q36063269-139AD3E7-AF31-4106-988D-97D5251058ED

Q36063269-21A9382F-8BD9-4386-9103-75EC1FCDD953

Q36063269-231823D9-53B7-4395-BD82-A19E250E09FD

Q36063269-2AB11C79-39AC-4893-9470-3A417D846D42

Q36063269-2B64C5EA-AEEE-430A-B2BE-7BA6C276D821

Q36063269-2D76609B-7E62-409F-B70F-47BE02D57EFB

Q36063269-39577727-9657-4435-925F-7B8D0F4E4D23

Q36063269-3D3B5B7A-0633-45E5-A411-97FBD8B849A6

Q36063269-44D2D582-789E-4728-B950-BA5EA0346398

P304

Q36063269-8ED97AF5-28EA-4BA5-80D3-1DE96221C351

P31

Q36063269-2EBA9D20-1EEE-4AA2-BD64-5FB027C55AAB

P356

Q36063269-13A4ABF3-2DFE-4BCB-94D4-B180262D9176

P407

Q36063269-B7F641CF-704F-404E-AB3B-5A89BACE88F1

P433

Q36063269-A57A996B-9C20-48CE-B3E3-08A3DEFA72CD

P478

Q36063269-6CA4A467-7F22-4C2A-8216-7E3FB789C036

P50

Q36063269-B2F781B2-577F-43DE-9285-D527EA7A6BE3

P577

Q36063269-B3C52405-B264-422A-8B8B-4233499538F0

P5875

Q36063269-22150024-8655-46C2-B78F-150513B5153B

P698

Q36063269-7652661B-D7BA-4EFE-B64D-05E4F2E33FDE

P921

Q36063269-70678B11-1F79-4881-92E5-044199994DEF

P932

Q36063269-CBB2513C-547D-4E78-AC79-072961D1BF7F

P356

P1433

P1476

Alterations in axonal transpor ...... erimental Parkinson's disease.

@en

P2093

Gerardo A Morfini

http://www.w3.org/2001/XMLSchema#string

Lori B Langhamer

http://www.w3.org/2001/XMLSchema#string

Scott T Brady

http://www.w3.org/2001/XMLSchema#string

Yaping Chu

http://www.w3.org/2001/XMLSchema#string

Yinzhen He

http://www.w3.org/2001/XMLSchema#string

P2860

The DYNLT3 light chain directly links cytoplasmic dynein to a spindle checkpoint protein, Bub3

Molecular motors implicated in the axonal transport of tau and alpha-synuclein

An isoform of kinesin light chain specific for the Golgi complex

Activity-dependent regulation of MEF2 transcription factors suppresses excitatory synapse number

Axonal transport defects: a common theme in neurodegenerative diseases

Identification and molecular characterization of the p24 dynactin light chain

Parkinson's disease: mechanisms and models

Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease.

Phosphorylation of synucleins by members of the Polo-like kinase family.

A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration.

P304

2058-2073

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/BRAIN/AWS133

http://www.w3.org/2001/XMLSchema#string

P407

P433

Pt 7

http://www.w3.org/2001/XMLSchema#string

P478

135

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey H Kordower

P577

2012-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227711029

http://www.w3.org/2001/XMLSchema#string

P698

22719003

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

4571141

http://www.w3.org/2001/XMLSchema#string